JANUS HENDERSON GROUP PLC - 16 Aug 2024 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Role: 10%+ Owner
Signature: /s/ Michelle Rosenberg, CAO, General Counsel & Company Secretary
Issuer symbol: ORKA
Transactions as of: 16 Aug 2024
Net transactions value: +$17,067
Form type: 4
Filing time: 20 Aug 2024, 14:23:17 UTC
Previous filing: 26 Jul 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABIO	Common Stock	Purchase	$15,793	+5,390	+0.26%	$2.93	2,116,785	16 Aug 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$1,274	+428	+0.02%	$2.98	2,117,213	16 Aug 2024	By Fund	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

Content

The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.